Product Pipeline

Urological Pipeline

Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
Vesique® (APL-1202)
MetAP2
Worldwide
China
NMIBC, intermediate/high risk, relapsed from chemotherapy (in combination with chemotherapy, second-line)
China
NMIBC, intermediate risk, untreated (single agent, first-line)
USA
NMIBC, intermediate/high risk, relapsed with BCG (in combination with BCG)
USA, China
Neoadjuvant therapy for MIBC (in combination with tislelizumab)
APL-1501
MetAP
Worldwide
Australia
Urological tumors
Hexvix® (APL-1706)
Photodynamic Detection Agent
China
NMIBC diagnosis and surgery
Uro-G/Uro-V (APLD-2101)
Single-use Cystoscopy
China
NMIBC diagnosis
IVES
Immunotherapy
Worldwide
NMIBC treatment

Other Diseases

Product
Target/Type
Region
Pre-Clinical
IND
Phase I
Phase II
Pivotal/Phase III
NDA
APL-1401
DBH
Worldwide
Moderately to severely active ulcerative colitis
ASN-1733
Undisclosed
Worldwide
Acinetobacter baumannii infection